Tere

Tere Therapeutics is a pre-clinical stage biotechnology company focused on developing novel therapies for rare genetic neuromuscular and skeletal diseases. The company's primary focus is on the development of small molecule inhibitors targeting TRPV4 mutations, which are known to cause conditions such as Charcot-Marie-Tooth disease type 2C (CMT2C) and various forms of skeletal dysplasia. By modulating the overactive ion channels caused by these genetic mutations, Tere Therapeutics aims to provide disease-modifying treatments for patients with limited therapeutic options. The company was founded by industry veterans with significant experience in rare disease drug development.